Glycine site agonists of the N-methyl-d-aspartate receptor and Parkinson's disease: A hypothesis

Movement Disorders

Volumn 28, Issue 4, 2013, Pages 419-424

  Heresco Levy, Uriel ^a   Shoham, Shai ^b   Javitt, Daniel C ^c  

^a HEBREW UNIVERSITY   (Israel)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^c Columbia University ^*  (United States)

Author keywords

GLY site agonists; NMDAR; Parkinson's disease

Indexed keywords

CYCLOSERINE; DEXTRO ALANINE; DEXTRO SERINE; GLYCINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR STIMULATING AGENT; PLACEBO;

ARTICLE; DIET SUPPLEMENTATION; DRUG MEGADOSE; DRUG TARGETING; DRUG TOLERABILITY; DYSKINESIA; EXCITOTOXICITY; HUMAN; MOTOR DYSFUNCTION; NERVE CELL PLASTICITY; NEUROMODULATION; NEUROTRANSMISSION; NUTRITIONAL SUPPORT; PARKINSON DISEASE; PRIORITY JOURNAL; SCHIZOPHRENIA; TARDIVE DYSKINESIA;

ANIMALS; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; GLYCINE; HUMANS; PARKINSON DISEASE; RECEPTORS, N-METHYL-D-ASPARTATE; SCHIZOPHRENIA;

EID: 84876149595     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.25306     Document Type: Article

References (47)

1. Johnson KA, Conn PJ, Niswender CM. Glutamate receptors as therapeutic targets for Parkinson's disease. CNS Neurol Disord Drug Targets. 2009;8:475-491.
2. Nash JE, Ravenscroft P, McGuire S, Crossman AR, Menniti FS, Brotchie JM. The NR2B-selective NMDA receptor antagonist CP-101, 606 exacerbates L-DOPA-induced dyskinesia and provides mild potentiation of anti-parkinsonian effects of L-DOPA in the MPTP-lesioned marmoset model of Parkinson's disease. Exp Neurol. 2004;188:471-479.
3. Hallett PJ, Dunah, AW, Ravenscroft P, et al. Alterations of striatal NMDA receptor subunits associated with the development of dyskinesia in the MPTP-lesioned primate model of Parkinson's disease. Neuropharmacology. 2005;48:503-516.
4. Gardoni F, Sgobio C, Pendolino V, Calabresi P, Di Luca M, Picconi B. Targeting NR2A-containing NMDA receptors reduces L-DOPA-induced dyskinesias. Neurobiol Aging. 2012;33:2138-2144
5. Laurie DJ, Seeburg PH. Ligand affinities at recombinant N-methyl-D-aspartate receptors depend on subunit composition. Eur J Pharmacol. 1994;268:335-345.
6. Kemp JA, Leeson PD. The glycine site of the NMDA receptor-five years on. Trends Pharmacol Sci. 1993;14:20-25.
7. Cotman CW, Monaghan DT, Ganong AH. Excitatory amino acid neurotransmission: NMDA receptors and Hebb-type synaptic plasticity. Annu Rev Neurosci. 1988;11:61-80.
8. Awad H, Hubert GW, Smith Y, Levey AI, Conn PJ. Activation of metabotropic glutamate receptor 5 has direct excitatory effects and potentiates NMDA receptor currents in neurons of the subthalamic nucleus. J Neurosci. 2000;20:7871-7879.
9. Marino MJ, Valenti O, Conn PJ. Glutamate receptors and Parkinson's disease: opportunities for intervention. Drugs Aging. 2003;20:377-397.
10. Waxman EA, Lynch DR. N-methyl-D-aspartate receptor subtypes: multiple roles in excitotoxicity and neurological disease. Neuroscientist. 2005;11:37-49.
11. Blanchet PJ, Konitsiotis S, Whittemore ER, Zhou ZL, Woodward RM, Chase TN. Differing effects of N-methyl-D-aspartate receptor subtype selective antagonists on dyskinesias in levodopa-treated 1-methyl-4-phenyl-tetrahydropyridine monkeys. J Pharmacol Exp Ther. 1999;290:1034-1040.
12. Leaver KR, Allbutt HN, Creber NJ, Kassiou M, Henderson JM. Neuroprotective effects of a selective N-methyl-D-aspartate NR2B receptor antagonist in the 6-hydroxydopamine rat model of Parkinson's disease. Clin Exp Pharmacol Physiol. 2008;35:1388-1394
13. 1 activation potentiates striatal NMDA receptors by tyrosine phosphorylation-dependent subunit trafficking. J Neurosci. 2006;6:4690-4700.
14. Chéremy A, L'hirondel M, Godeheu G, et al. Direct and indirect presynaptic control of dopamine release by excitatory amino acids. Amino Acids. 1998;14:63-68.
15. Zigmond MJ, Castro SL, Keefe KA, Abercrombie ED, Sved AF. Role of excitatory amino acids in the regulation of dopamine synthesis and release in the neostriatum. Amino Acids. 1998;4:57-62.
16. Shoham S, Mazeh M, Javitt DC, Heresco-Levy U. Glycine and D-cycloserine attenuate vacuous chewing movements in a rat model of tardive dyskinesia. Brain Res. 2004;1004:142-147.
17. Ho Y, Mo S, Pawlak CR, Yeh K. Effects of D-cycloserine on MPTP-induced behavioral and neurological changes; potential for treatment of Parkinson's disease dementia. Behav Brain Res. 2011;219:280-290.
18. Schneider GS, Tinker JP, Van Velson M, Giardiniere M. Effects of the partial glycine agonist D-cycloserine on cognitive functioning in chronic low-dose MPTP-treated monkeys. Brain Res. 2000;860:190-194.
19. Calon F, Morissette M, Ghribi O, et al. Alteration of glutamate receptors in the striatum of dyskinetic 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-treated monkeys following dopamine agonist treatment. Prog Neuropsychopharmacol Biol Psychiatry. 2002;26:127-138.
20. Shoham S, Javitt DC, Heresco-Levy U. Chronic high-dose glycine nutrition: effects on rat brain cell morphology. Biol Psychiatry. 2001;49:876-885.
21. Heresco-Levy U. Amino acid transmitter systems in schizophrenia and other psychotic disorders. In: D'haenen H, den Boer JA, Westenberg M, Willner P, eds. Biological Psychiatry. London: John Wiley & Sons; 2002:587-600.
22. Javitt DC. Glutamate as a therapeutic target in psychiatric disorders. Mol Psychiatry. 2004: 9:1-4.
23. Dalmau J, Lancaster E, Martinez-Hernandez E, Rosenfeld MR, Balice-Gordon, R Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurol. 2011;10:63-64.
24. Tsai GE, Lin P. Strategies to enhance N-methyl-D-aspartate receptor-mediated neurotransmission in schizophrenia: a critical review and data-analysis. Curr Pharm Design. 2010;16:522-537.
25. Heresco-Levy U, Javitt DC, Ebstein R, et al. D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia. Biol Psychiatry. 2005;57:577-585.
26. Heresco-Levy U, Javitt DC, Ermilov M, Lichtenberg P, Bar G. High dose glycine added to olanzapine and risperidone for the treatment of schizophrenia. Biol Psychiatry. 2004;2:165-171.
27. Kantrowitz JT, Malhotra AK, Cornblatt BA, et al. High dose D-serine in the treatment of schizophrenia. Schizo Res. 2010;121:125-130.
28. Heresco-Levy U, Javitt DC, Ermilov M, Mordel C, Silipo G, Lichtenstein M. Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia. Arch Gen Psychiatry. 1999;56:29-36.
29. Simpson GM, Angus JWS. A rating scale for extrapyramidal side effects. Acta Psych Scand. 1970;212(Suppl):11-19.
30. Guy W. ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: US Department of Health, Education and Welfare Publication (ADM); 1976:76-338.
31. Leentjens, AFG, Dujardin K, Marsh L, et al. Apathy and anhedonia rating scales in Parkinson's disease: critique and recommendations. Mov Disord. 2008;23:2004-2014.
32. Schrag A. Apathy and depression scales in Parkinson's disease. Are they good enough? J Neurol Sci. 2011;310:216-219.
33. Bogdanova Y, Cronin-Golomb A. Neurocognitive correlates of apathy and anxiety in Parkinson's disease. Parkinsons Dis. 2012;2012:793076.
34. Gelfin E, Kaufman Y, Korn-Lubetsky I, et al. D-serine adjuvant treatment alleviates behavioural and motor symptoms in Parkinson's disease. Int J Neuropsychopharmacol. 2012;15:543-549.
35. Kay SR, Opler LA, Fiszbein A. Positive and Negative Syndrome Scale (PANSS) Rating Manual. San Rafael, CA: Social and Behavioral Sciences Documents; 1987.
36. Calabresi P, Maj R, Pisani A, Mercuri NB, Bernardi G. Long-term synaptic depression in the striatum: physiological and pharmacological characterization. J Neurosci. 1992;12:4224-4233.
37. Centonze D., Gubellini P, Picconi B, Calabresi P, Giacomini P, Bernardi GJ. Unilateral dopamine denervation blocks corticostriatal LTP. J Neurophysiol. 1999;82:3575-3579.
38. Paillé V, Picconi B, Bagetta V, et al. Distinct levels of dopamine denervation differentially alter striatal synaptic plasticity and NMDA receptor subunit composition. J Neurosci. 2010;30:14182-14193.
39. Picconi B, Gardoni F, Centonze D, et al. Abnormal Ca2+-calmodulin-dependent protein kinase II function mediates synaptic and motor deficits in experimental parkinsonism. J Neurosci. 2004;24:5283-5291.
40. Gardoni F, Picconi B, Ghiglieri V, et al. A critical interaction between NR2B and MAGUK in L-DOPA induced dyskinesia. J Neurosci. 2006;26:2914-2922.
41. Nash JE, Brotchie JM. Characterisation of striatal NMDARs involved in the generation of parkinsonian symptoms: intrastriatal microinjection studies in the 6-OHDA-lesioned rat. Mov Disord. 2002;17:455-466.
42. Nikam SS, Meltzer LT. NR2B selective NMDA receptor antagonists. Curr Pharm Des. 2002;8:845-855.
43. MacDonald JF, Jackson MF, Beazely MA. Hippocampal long-term synaptic plasticity and signal amplification of NMDA receptors. Crit Rev Neurobiol. 2006;18:71-84.
44. Li P, Li YH, Han TZ. NR2A-containing NMDA receptors are required for LTP induction in rat dorsolateral striatum in vitro. Brain Res. 2009;1274:40-46.
45. Balan L, Foltyn VN, Zehl M, et al. Feedback inactivation of D-serine synthesis by NMDA receptor-elicited translocation of serine racemase to the membrane. Proc Natl Acad Sci USA. 2009;106:7589-7594.
46. Mustafa AK, Kumar M, Selvakumar B, et al. Nitric oxide S-nitrosylates serine racemase, mediating feedback inhibition of D-serine formation. Proc Natl Acad Sci U S A. 2007;104:2950-2955.
47. Burnet PW, Anderson PN, Chen L, Nikiforova N, Harrison PJ, Wood MJ. D-amino acid oxidase knockdown in the mouse cerebellum reduces NR2A mRNA. Mol Cell Neurosci. 2011;46:167-175.